PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Otava Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd - OTAVA Ltd. offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b - OtavaChemicals.com
DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd

 

NewswireToday - /newswire/ - Toronto, Ontario, Canada, 2014/03/11 - OTAVA Ltd. offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b - OtavaChemicals.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

DNA methylation is a major epigenetic modification which plays an important role in controlling gene expression, differentiation and embryonic development. This covalent modification of DNA in mammals is catalyzed by a family of enzymes called methyltransferases.

Methylation abnormalities were identified in both low and high-grade malignancies, supporting the idea that methylation changes can be an early event in tumor progression. Certain tumor types, like colon, glioma, and acute myeloid leukemia, display significantly higher frequency of aberrant methylation events. Therefore, methyltransferases, including DNMT1, 3a and 3b are involved in the progression of many malignant tumors and small compounds inhibiting these enzymes can be used for cancer treatment.

OTAVA Ltd (otavachemicals.com) offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b. Both libraries comprise drug-like compounds only. DNMT1 focused library comprises 503 compounds and DNMT3b targeted library 1320 compounds. The libraries were designed with virtual screening of Drug-like Green Collection. The results of virtual screening were validated with a reference set of known DNMT inhibitors obtained from ChemblDB. Final selection of compounds has been made with inspection of intermolecular hydrogen bonds of ligands with crucial active site’s residues taken from literature reviews, docking score cut-off filtering and exclusion of predicted DNMT1 and DNMT3b cross-binders. Also, 3D pharmacophore model consisting of two hydrogen bond donors, two hydrogen bond acceptors and a hydrophobic region has been applied during the selection.

These libraries provide an excellent basis for development of novel cancer therapeutics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Otava Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Andrey Dmytrenko - OtavaChemicals.com 
416-549-8030 eurasia[.]otavachemicals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Otava Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Otava Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)